tiprankstipranks
TipRanksStock Market NewsIKT NewsAnalysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT) and Mustang Bio (MBIO)
Blurbs

Analysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT) and Mustang Bio (MBIO)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inhibikase Therapeutics (IKTResearch Report) and Mustang Bio (MBIOResearch Report) with bullish sentiments.

Inhibikase Therapeutics (IKT)

In a report issued on November 17, Soumit Roy from JonesTrading maintained a Buy rating on Inhibikase Therapeutics, with a price target of $12.00. The company’s shares closed last Friday at $1.90, close to its 52-week low of $1.72.

According to TipRanks.com, Roy is a 5-star analyst with an average return of 24.5% and a 37.9% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Actinium Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inhibikase Therapeutics with a $12.00 average price target.

See today’s best-performing stocks on TipRanks >>

Mustang Bio (MBIO)

B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Mustang Bio on November 17 and set a price target of $13.00. The company’s shares closed last Friday at $2.27, close to its 52-week low of $2.10.

According to TipRanks.com, Mamtani is a 3-star analyst with an average return of 3.7% and a 40.1% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mustang Bio with a $10.00 average price target, implying a 340.5% upside from current levels. In a report issued on November 12, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on IKT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More